Gout management: targets and guideline differences
Prepared 2026-10-29 · Read as Markdown
Use the original guideline and current local prescribing information for decisions. This reference retains selected differences between ACR and NICE; recommendation strength and certainty of evidence are separate concepts. [S02] [S03]
Indications for urate-lowering treatment
ACR strongly recommends ULT for subcutaneous tophi, gout-attributable imaging damage, or at least two flares yearly. Infrequent recurrent disease and selected first-flare scenarios receive conditional recommendations. NICE offers ULT for multiple or troublesome flares, CKD stages 3–5, diuretic treatment, tophi, or chronic gouty arthritis, with broader discussion after a flare. S02 S03
Compare the strategies explicitly
| Topic | ACR 2020 | NICE NG219 |
|---|---|---|
| Initial agent | Allopurinol preferred, including in CKD | Allopurinol or febuxostat; allopurinol with major cardiovascular disease |
| Timing | Conditionally favors starting indicated ULT during a flare | Usually at least 2–4 weeks after resolution; may start during frequent flares |
| Target | Below 6 mg/dL; no lower numerical target specified in this guideline | Below 360 µmol/L; consider below 300 with tophi, chronic gouty arthritis, or persistent frequent flares despite usual target |
| Early-flare prophylaxis | At least 3–6 months, reassessing and extending if needed | Discuss benefits and risks; offer colchicine while reaching target if prophylaxis is chosen, with alternatives by suitability |
Both approaches require measured urate-guided titration rather than an ineffective fixed starting dose. S02 S03
Product safety remains specific
Review HLA-B*58:01 testing indications, allopurinol hypersensitivity and thiopurine interactions; colchicine inhibitor and renal/hepatic restrictions; febuxostat’s US cardiovascular warning; probenecid renal and stone limitations; and pegloticase and canakinumab labeling. A class-level statement must not override product instructions. S09 S10 S11 S12 S13 S14
Follow-up and interpretation
NICE uses monthly urate checks to guide titration and considers annual monitoring after reaching target during continuing ULT. Trial support for education, engagement, and active titration concerns the package of care. It cannot be reduced to information alone or extended into unproven cardiovascular or renal protection claims. S03 S24
Related pages
- Targets, monitoring and follow-up
- Medicine interactions and safety
- Specialist and advanced gout treatment
- Sources and guidelines
Sources
- S02: 2020 American College of Rheumatology Guideline for the Management of Gout
- S03: NICE NG219: Gout, diagnosis and management, recommendations
- S09: DailyMed: Allopurinol tablets prescribing information
- S10: DailyMed: Colchicine tablets prescribing information
- S11: DailyMed: ULORIC febuxostat prescribing information
- S12: DailyMed: Probenecid tablets prescribing information
- S13: DailyMed: KRYSTEXXA pegloticase prescribing information
- S14: DailyMed: ILARIS canakinumab prescribing information
- S24: Doherty et al.: Nurse-led education and treat-to-target gout care trial